



Attorney Ref #: 346B USC1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gilman et al.  
Serial No.: 10/002,244  
Filed : October 23, 2001  
For : *Use of Heterologous Transcription  
Factors in Gene Therapy*

Art Unit: 1632

Examiner: ---

Assistant Commissioner for Patents  
Washington, DC 20231

January 23, 2002

**Information Disclosure Statement Under 37 CFR §1.97(B)**

Applicants and their agents/attorneys are aware of the following publications and information, and in accordance with 37 C.F.R. § 1.97 and § 1.98, wish to make them of record. Form PTO-1449 and a copy of each publication listed thereon are enclosed. The Examiner is respectfully requested to initial the space adjacent to each documents on the PTO-1449 form and return a copy of the PTO-1449 form to confirm that these documents have been considered by the Examiner and made of record in this application.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited publications.

No additional costs are believed to be due in connection with the filing of this disclosure. However, please charge any necessary fees to our Deposit Account No. 01-2315. Should there be any questions after review of this paper, the Examiner is invited to contact the undersigned at (617) 494-0400 x266.

Respectfully submitted,

David L. Bernstein, Reg No. 31,235  
ARIAD Pharmaceuticals, Inc.  
26 Landsdowne Street  
Cambridge, MA 02139  
Telephone: 617-494-0400 Ext. 266  
Facsimile: 617-494-0208


I hereby certify that this paper is being deposited with the United States Postal Service via First Class Mail under 37 CFR 1.08 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, DC 20231

Date Jan. 23, 2002 Signed

Sue Wilson

Vern Trombly

Form PTO-1449 (Modified)	ATTY. DOCKET NO. <b>346B USC1</b>	SERIAL NO. <b>10/002,224</b>
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: <b>Gilman</b>	
	FILING DATE: <b>10/23/01</b>	GROUP <b>1632</b>



### U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	Filing Date If Appropriate
		5,830,462	11/3/98	Crabtree et al.	424	93.21	6/7/95
		5,654,168	08/05/97	Bujard et al.	435	69.1	
		5,082,670	1/21/92	Gage et al.	424		
		5,262,300	11/16/93	Evans et al.	435	6	
		5,534,418	7/9/96	Evans et al.	435	69.1	
		5,597,693	1/28/97	Evans et al.	435	6	

### FOREIGN PATENT DOCUMENTS

Exam Init	Ref Des	Country & Doc. No. (11)	Pub. Date (43)	Name	Class	Sub Class	Translation Yes	No
		✓ WO 97/12040	4/3/97	Anrather et al.				
		✓ WO 96/41865	12/ 27/96	Clackson et al.				

### OTHER ART

(Including Author, Date, Publication, Title, Pertinent Pages)

		1	Ruben et al., (1992) Mol Cell Biol 12:444-454.
		2	Blair et al., (1994) Mol Cell Biol 14:7226-7234.
		3	Emami and Carey (1992) EMBO J. 11:5005-5012.
		4	Kodadek and Johnston (1995) Chemistry and Biology 2:187-194.
		5	Paal (1997) Nucleic Acids Research, 25(5): 1050-1055.
		6	Lin et al., (1988) Cell, 54: 659-664.
		7	Schmitz et al., (1995) J. Biol. Chem., 270: 15576-15584.
		8	White et al., (1992 ) EMBO J. Jun;11(6):2229-40.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Please include copy of this form with next communication to Applicant.

Form PTO-1449 (Modified)

ATTY. DOCKET NO. **346B USC1**SERIAL NO. **10/002,224**LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENTAPPLICANT: **Gilman**FILING DATE: **10/23/01**GROUP **1632****OTHER ART**

(Including Author, Date, Publication, Title, Pertinent Pages)

		Hollenberg and Evans, (1988) Cell, 55: 889-906.
	10	Tate et al., (1996) FASEB J., 10: 1524-1531.
	11	Sauer, (1995) Science 270: 1783-1788.
	12	Sublett et al., (1995) Oncogene, Aug 3; 11(3): 545-52.
	13	Le Douarin et al., (1995) Nucleic Acids Research, 23: 876-878.
	14	Oligino et al., (1996) Gene Therapy, 8: 892-899.
	15	Veelken et al., (1998) Int J Mol. Med., 2(4): 423-428.
	16	Liu et al., (1993) Immunology Today, 14:290-295, 1993.
	17	Orkin et al., (1995) Report & Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy
	18	Orloff et al., (1990) Nature 347:189-190.
	19	Qi et al., (1995) Mol Cell Biol., 5:1817-1825.
	20	Sadowski et al., (1993) Nature 362:79-83.
	21	Weintraub et al., (1991) Science 251:761-766.
	22	Fishman et al., (1994) J. Clin. Invest. 93:1864-1868.
	23	Bergmann et al., (1994) J. Steroid Biochem. Molec. Biol., 49:139-152.
	24	Li and Brasler, (1996) Molecular Endocrinology 10:252-264.
	25	Baim et al., (1991) Proc Natl Acad Sci USA 88:5072-5076.
	26	Pruschy et al., (1994) Chemistry & Biology, 1(3): 163-171.
	27	Becker et al., (1989) Mol. Cell. Biol., 9(9): 3878-3887.
	28	Chapman et al., (1996) Mol. Endocrinol., 10: 967-978.
	29	Schmitz and Baeuerle (1991) EMBO J. 10:3805-3817.
	30	Selden et al., (1987) Science 236:714-718.
	31	Burcin et al., (1999) Proc Natl Acad Sci USA 96:355-360.
	32	Rivera et al., (1996) Nature Medicine 2:1028-1032.
	33	Rivera et al., (1999) Proc Natl Acad Sci USA 96:8657-8662.
	34	Ye et al., (1999) Science 283:88-91.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Please include copy of this form with next communication to Applicant.